7 research outputs found
Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12
Intratumoral injection of Semliki Forest virus encoding interleukin-12 (SFV-IL-12) combines acute expression of IL-12 and stressful apoptosis of infected malignant cells. Agonist antibodies directed to costimulatory receptor CD137 (4-1BB) strongly amplify pre-existing cellular immune responses toward weak tumor antigens. In this study, we provide evidence for powerful synergistic effects of a combined strategy consisting of intratumoral injection of SFV-IL-12 and systemic delivery of agonist anti-CD137 monoclonal antibodies (mAbs), which was substantiated against poorly immunogenic B16 melanomas (B16-OVA and B16.F10) and TC-1 lung carcinomas. Effector CD8(β)(+) T cells were sufficient to mediate complete tumor eradications. Accordingly, there was an intensely synergistic in vivo enhancement of cytotoxic T lymphocytes (CTL)-mediated immunity against the tumor antigens OVA and tyrosine-related protein-2 (TRP-2). This train of phenomena led to long-lasting tumor-specific immunity against rechallenge, attained transient control of the progression of concomitant tumor lesions that were not directly treated with SFV-IL-12 and caused autoimmune vitiligo. Importantly, we found that SFV-IL-12 intratumoral injection induces bright expression of CD137 on most tumor-infiltrating CD8(+) T lymphocytes, thereby providing more abundant targets for the action of the agonist antibody. This efficacious combinatorial immunotherapy strategy offers feasibility for clinical translation since anti-CD137 mAbs are already undergoing clinical trials and development of clinical-grade SFV-IL-12 vectors is in progress
Vitamin D protects against oxidative stress and inflammation in human retinal cells
Diabetic retinopathy is a vision-threatening microvascular complication of diabetes and is
one of the leading causes of blindness. Oxidative stress and inflammation play a major role in its
pathogenesis, and new therapies counteracting these contributors could be of great interest. In the
current study, we investigated the role of vitamin D against oxidative stress and inflammation in
human retinal pigment epithelium (RPE) and human retinal endothelial cell lines. We demonstrate
that vitamin D effectively counteracts the oxidative stress induced by hydrogen peroxide (H2O2).
In addition, the increased levels of proinflammatory proteins such as Interleukin (IL)-6, IL-8, Monocyte
chemoattractant protein (MCP)-1, Interferon (IFN)-γ, and tumor necrosis factor (TNF)-α triggered by
lipopolysaccharide (LPS) exposure were significantly decreased by vitamin D addition. Interestingly,
the increased IL-18 only decreased by vitamin D addition in endothelial cells but not in RPE cells,
suggesting a main antiangiogenic role under inflammatory conditions. Moreover, H2O2 and LPS
induced the alteration and morphological damage of tight junctions in adult retinal pigment epithelium
(ARPE-19) cells that were restored under oxidative and inflammatory conditions by the addition of
vitamin D to the media. In conclusion, our data suggest that vitamin D could protect the retina by
enhancing antioxidant defense and through exhibiting anti-inflammatory properties
Vitamin D protects against oxidative stress and inflammation in human retinal cells
Diabetic retinopathy is a vision-threatening microvascular complication of diabetes and is
one of the leading causes of blindness. Oxidative stress and inflammation play a major role in its
pathogenesis, and new therapies counteracting these contributors could be of great interest. In the
current study, we investigated the role of vitamin D against oxidative stress and inflammation in
human retinal pigment epithelium (RPE) and human retinal endothelial cell lines. We demonstrate
that vitamin D effectively counteracts the oxidative stress induced by hydrogen peroxide (H2O2).
In addition, the increased levels of proinflammatory proteins such as Interleukin (IL)-6, IL-8, Monocyte
chemoattractant protein (MCP)-1, Interferon (IFN)-γ, and tumor necrosis factor (TNF)-α triggered by
lipopolysaccharide (LPS) exposure were significantly decreased by vitamin D addition. Interestingly,
the increased IL-18 only decreased by vitamin D addition in endothelial cells but not in RPE cells,
suggesting a main antiangiogenic role under inflammatory conditions. Moreover, H2O2 and LPS
induced the alteration and morphological damage of tight junctions in adult retinal pigment epithelium
(ARPE-19) cells that were restored under oxidative and inflammatory conditions by the addition of
vitamin D to the media. In conclusion, our data suggest that vitamin D could protect the retina by
enhancing antioxidant defense and through exhibiting anti-inflammatory properties
Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L
Peptide vaccines derived from CD8+ T-cell epitopes have shown variable efficacy in cancer patients. Thus, some peptide vaccines are capable of activating CD8+ T-cell responses, even in the absence of CD4+ T-cell epitopes or dendritic cell
(DC)-activating adjuvants. However, the mechanisms underlying the clinical activity of these potent peptides are poorly
understood. Using CT26 and ovalbumin-expressing B16 murine allograft tumor models, we found that the antitumor
effect of helper cell-independent CD8 T-cell peptide vaccines is inhibited by the blockade of CD40 ligand (CD40L) in vivo.
Furthermore, in vitro stimulation with antigenic peptides of cells derived from immunized mice induced the expression
of CD40L on the surface of CD8+ T cells and fostered DC maturation, an effect that was partially inhibited by CD40L-blocking antibodies. Interestingly, CD40L blockade also inhibited CD8+ T-cell responses, even in the presence of fully mature
DCs, suggesting a role for CD40L not only in promoting DC maturation but also in mediating CD8+ T-cell co-stimulation.
Importantly, these potent peptides share features with bona fide CD4 epitopes, since they foster responses against less
immunogenic CD8+ T-cell epitopes in a CD40L-dependent manner. The analysis of peptides used for the vaccination of
cancer patients in clinical trials showed that these peptides also induce the expression of CD40L on the surface of CD8+
T cells. Taken together, these results suggest that CD40L expression induced by potent CD8+ T-cell epitopes can activate
antitumor CD8+ T-cell responses, potentially amplifying the immunological responses to less immunogenic CD8+ T-cell
epitopes and bypassing the requirement for CD4+ helper T cells in vaccination protocols
Matrix metalloproteinase 13 is associated with age-related choroidal neovascularization
Age-related macular degeneration (AMD) is a leading cause of severe vision loss in older individuals in developed countries. Despite advances in our understanding of AMD, its pathophysiology remains poorly understood. Matrix metalloproteinases (MMPs) have been proposed to play a role in AMD development. In this study, we aimed to characterize MMP-13 in AMD. We used retinal pigment epithelial cells, a murine model of laser-induced choroidal neovascularization, and plasma samples from patients with neovascular AMD to conduct our study. Our results show that MMP13 expression significantly increased under oxidative stress conditions in cultured retinal pigment epithelial cells. In the murine model, MMP13 was overexpressed in both retinal pigment epithelial cells and endothelial cells during choroidal neovascularization. Additionally, the total MMP13 levels in the plasma of patients with neovascular AMD were significantly lower than those in the control group. This suggests a reduced diffusion from the tissues or release from circulating cells in the bloodstream, given that the number and function of monocytes have been reported to be deficient in patients with AMD. Although more studies are needed to elucidate the role of MMP13 in AMD, it could be a promising therapeutic target for treating AMD
Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy
Transforming growth factor-beta (TGF-beta) is a cytokine with potent immunosuppressive effects and is overexpressed in many tumors. Therefore, development of molecules able to inhibit TGF-beta is of paramount importance to improve the efficacy of antitumor immunotherapy. TGF-beta inhibitor peptides P144 and P17 were combined with the administration of adjuvant molecules poly(I:C) and agonistic anti-CD40 antibodies, and their effect on the growth of E.G7-OVA established tumors and on antitumor immune response was evaluated. Tumor rejection efficacy of a single administration of adjuvants was enhanced from 15 to 70 % when combined with repeated injections of TGF-beta inhibitor peptides. Simultaneous administration of adjuvants and TGF-beta inhibitor peptides was required for maximal therapeutic efficacy. Although tumor cells produced TGF-beta, it was found that the beneficial effect of peptide administration was mainly due to the inhibition of TGF-beta produced by regulatory CD4(+)CD25(+) T cells rather than by tumor cells. The enhanced antitumor effect was accompanied by a higher activity of dendritic cells, natural killer cells and tumor antigen-specific T cells, as well as by a decrease in the number of myeloid-derived suppressor cells. In conclusion, administration of peptide inhibitors of TGF-beta in therapeutic vaccination enhances the efficacy of immunotherapy by increasing antitumor immune responses. These peptide inhibitors may have important applications for current immunotherapeutic strategies
In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1
Down-regulation of CD4+CD25+ regulatory T (Treg) cell function might be beneficial to enhance the immunogenicity of viral and tumor vaccines or to induce breakdown of immunotolerance. Although the mechanism of suppression used by Treg cells remains controversial, it has been postulated that TGF-beta1 mediates their immunosuppressive activity. In this study, we show that P17, a short synthetic peptide that inhibits TGF-beta1 and TGF-beta2 developed in our laboratory, is able to inhibit Treg activity in vitro and in vivo. In vitro studies demonstrate that P17 inhibits murine and human Treg-induced unresponsiveness of effector T cells to anti-CD3 stimulation, in an MLR or to a specific Ag. Moreover, administration of P17 to mice immunized with peptide vaccines containing tumor or viral Ags enhanced anti-vaccine immune responses and improved protective immunogenicity against tumor growth or viral infection or replication. When CD4+ T cells purified from OT-II transgenic mice were transferred into C57BL/6 mice bearing s.c. EG.7-OVA tumors, administration of P17 improved their proliferation, reduced the number of CD4+Foxp3+ T cells, and inhibited tumor growth. Also, P17 prevented development of immunotolerance induced by oral administration of OVA by genetically modified Lactococcus lactis in DO11.10 transgenic mice sensitized by s.c. injection of OVA. These findings demonstrate that peptide inhibitors of TGF-beta may be a valuable tool to enhance vaccination efficacy and to break tolerance against pathogens or tumor Ags